Artiva Biotherapeutics ARTV Ratios (2023-2026)

NASDAQ ARTV
$11.19 +0.06 (+0.58%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Artiva Biotherapeutics Quarterly Ratios

Periods 13 quarters
Latest Jun 2026

Artiva Biotherapeutics ratios data for the quarter ended Jun 2026. These financial ratios cover 13 quarters of results from Jun 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Profitability
EBT Margin -323.56%42.13%-484.55%-5,514.74%
EBIT Margin -338.12%40.56%-509.36%-5,773.71%
EBITDA Margin -338.12%40.56%-509.36%-5,773.71%
Operating Margin -338.12%40.56%-509.36%-5,773.71%
Net Margin -323.56%42.13%-484.55%-5,514.74%
FCF Margin -40.99%-481.32%-5,998.01%
Efficiency
Assets AverageAssets Avg. 150.75M217.59M200.42M180.33M159.13M139.90M118.45M237.29M
Asset Utilization RatioAsset Util. 0.020.00
Valuation
Price to EarningsP/E -17.71-7.05-3.60-1.74-3.27-5.11-6.77-15.29
Price to BookP/B 1.450.610.430.250.550.961.811.10
Enterprise Value 145.33M-71.94M-92.87M-105.48M-150.02M-1.97M6.55M-15.03M
EV to EBIT -7.933.944.194.626.550.09-0.270.56
EV to EBITDA -7.933.944.194.626.550.09-0.270.56
Market Capitalization 291.96M113.49M73.09M36.88M70.44M106.03M159.18M382.31M
Price to FCFP/FCF -24.94-7.71-3.53-1.56-3.56-6.98-7.47-18.50
EV to FCF -12.414.894.484.467.580.13-0.310.73
EV to CFO -12.524.914.684.597.810.13-0.310.74
Return Ratios
Return on Sales [ROS]ROS -338.12%40.56%-509.36%-5,773.71%-108.83%-2,344.75%-26,806.37%
Return on Capital Employed [ROCE]ROCE -44.37%-32.77%-39.83%-48.11%-58.20%-70.82%-85.59%-43.17%
Return on Assets [ROA]ROA -37.96%-28.46%-34.13%-41.11%-49.75%-59.94%-73.50%-38.27%